Eli Lilly's Obesity Drug Prescriptions Lag Behind Novo Nordisk's Wegovy
Eli Lilly's weight loss drugs, Foundayo and Zepbound, have lower weekly prescription rates compared to Novo Nordisk's Wegovy, according to IQVIA data. This has led to a premarket decline in Eli Lilly's stock. The data highlights the competitive landscape in the obesity drug market.
Topics: Eli Lilly market competition stock price movement weight loss therapies